ArticlemedRxiv : the preprint server for health sciences2025
PSA/testosterone ratio as a potential biomarker to identify early progressors of adaptive therapy in metastatic castration sensitive prostate cancer.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeWe aim to identify biomarkers of progression in an ongoing pilot trial using adaptive dosing in metastatic castrate sensitive prostate cancer (mCSPC). PATIENTS AND
methodsMen with mCSPC were given combined androgen deprivation therapy with an androgen receptor signaling inhibitor followed by a treatment break after achieving >75% PSA decline. This was followed by evolution-informed drug cycling to prevent resistance outgrowth. Just 6 of 16 patients have progressed at month 55, and we wish to identify predictive features that would help identify these patients. We compare clinical features, testosterone metrics, and PSA metrics over the trial cohort, and we fit a mathematical model to the dynamic patient-specific data to gain more mechanistic insight as to what might be driving early progression.
resultsSignificant clinical risk factors predicting progression included the risk status, the number of bone metastases, and the total number of metastases. However, analyses of the dynamical changes in PSA and testosterone during the initial cycle of treatment identified several useful features to discriminate early, late, and non-progressors. Specifically, a higher PSA at the end of the induction phase, a lower percent change in PSA over the induction period, and a higher average PSA/Testosterone ratio over the first cycle significantly predicted progressors. Thresholds for these metrics are able to distinguish the earliest progressors. A simple mathematical model coupling the PSA and the testosterone dynamics suggests a higher fraction of resistant cells exist prior to therapy for those that progress earlier.
conclusionPSA/Testosterone ratio is a useful feature to couple drug response to tumor burden dynamics and predict early progression from the first cycle of adaptive therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.